Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sercan Aksoy

Showing results (201-210 of 206) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 206 results.
Therapeutic Advances in Medical Oncology|March 16, 2026
Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter studyTaha Koray Sahin, Fatih Kemik, Harun Muglu, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudyMustafa Seyyar, Ali Kalem, Mürsel Sali, et al.
International Journal of Cancer|October 28, 2025
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology GroupSalih Tunbekici, Gokhan Sahin, Sercan Ön, et al.
Clinical Breast Cancer|April 7, 2025
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySeda Kahraman, Enes Erul, Ozge Gumusay, et al.
Future Oncology (London, England)|May 3, 2023
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancerSeda Kahraman, Enes Erul, Mustafa Seyyar, et al.
BMC Cancer|February 11, 2023
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapyCengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, et al.
Pageof 21

Showing results (201-210 of 206) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 206 results.
Therapeutic Advances in Medical Oncology|March 16, 2026
Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter studyTaha Koray Sahin, Fatih Kemik, Harun Muglu, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudyMustafa Seyyar, Ali Kalem, Mürsel Sali, et al.
International Journal of Cancer|October 28, 2025
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology GroupSalih Tunbekici, Gokhan Sahin, Sercan Ön, et al.
Clinical Breast Cancer|April 7, 2025
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySeda Kahraman, Enes Erul, Ozge Gumusay, et al.
Future Oncology (London, England)|May 3, 2023
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancerSeda Kahraman, Enes Erul, Mustafa Seyyar, et al.
BMC Cancer|February 11, 2023
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapyCengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, et al.
Pageof 21